---
title: "Short- and Long-term Outcomes of Robotic vs Laparoscopic Right Colon Cancer: a 10-year Single-center Retrospective Study"
nct_id: NCT06454253
overall_status: COMPLETED
sponsor: Taiyuan Li
study_type: OBSERVATIONAL
primary_condition: Robotic
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06454253.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06454253"
ct_last_update_post_date: 2024-06-12
last_seen_at: "2026-05-12T06:25:24.585Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Short- and Long-term Outcomes of Robotic vs Laparoscopic Right Colon Cancer: a 10-year Single-center Retrospective Study

**Official Title:** the Ethics Committee of the First Affiliated Hospital of Nanchang University

**NCT ID:** [NCT06454253](https://clinicaltrials.gov/study/NCT06454253)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 1879
- **Lead Sponsor:** Taiyuan Li
- **Conditions:** Robotic, Laparoscopic, Colon Cancer, Long-term Outcomes, Short-term Outcomes
- **Start Date:** 2014-12-01
- **Completion Date:** 2024-04-30
- **CT.gov Last Update:** 2024-06-12

## Brief Summary

The goal of this observational study is to evaluate the short-term outcomes and long-term outcomes of robot-assisted right colon group for cancer compared to laparoscopic-assisted right colon group. This is a large sample study based on ten years of clinical data. The main question it aims to answer is: What are the advantages of da Vinci robot right hemicolectomy compared to laparoscopic right hemicolectomy, and is there a difference in long-term efficacy between the two methods.

## Detailed Description

Colorectal cancer (CRC) is highly prevalent worldwide. In China, CRC ranks high among the population of men and women with cancer. The incidence and mortality rates of CRC are rising quickly in developing countries, and it is the fourth most deadly cancer in the world. In particular, the right colon cancer (RCC) is continuously growing in China, and the early symptoms of RCC are not typical. one of the most useful ways for RCC is surgical is a surgical operation. Along with the development of minimally invasive surgery, the use of laparoscopy for colon cancer is widely accepted and has become one symbolic surgical technology. Studies have demonstrated that laparoscopic colonic surgery is related to reduced pain after operation, shorter rehabilitation time, shorter length of hospital stay, reduced the time of ileus after surgery, and reduced surgical site infection.

Nevertheless, laparoscopic surgery also has its shortcoming, including a limited range of motion, slow learning and growth, and physiological tremor cannot be eliminated.The emergence of robots has broken the inherent disadvantage of laparoscopy. It has achieved similar or better results in previous studies. Based on these advantages, robotic surgery has received much attention from the surgeons. With the first robotic surgery in the field of colon cancer was reported in 2002, there are some studies proved the safety and feasibility by using robot,However, most studies with small sample sizes and with cases at a relatively early stage.

Therefore, the purpose of this study is to compare the short-term and long-term outcomes between RARC and LARC in the treatment of right colon cancer in our center.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 85 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. The age is more than 18 years old and less than or equal to 85 years old
2. No distant metastasis (including pelvic cavity, peritoneum, liver, lung, brain, bone, distant lymph node metastasis, etc.) is judged by ultrasound, CT, PET-CT, etc
3. Preoperative colonoscopy showing that the tumor was located in the ileocecal region, ascending colon, hepatic flexure, or transverse colon with pathology showing malignancy
4. signed informed consent. -

Exclusion Criteria:

1. multiple primary colorectal cancer
2. recurrent right colon cancer
3. preoperative neoadjuvant chemotherapy
4. emergency surgery for intestinal obstruction, bleeding or perforation
5. incomplete data and missing follow-up data. -
```

## Arms

- **robot-assisted right colon group** — Robot assisted radical surgery for right colon cancer
- **laparoscopic-assisted right colon group** — Laparoscopic assisted radical surgery for right colon cancer

## Interventions

- **Da Vinci Robot Surgical System** (DEVICE) — Performing surgery on right colon cancer patients using the da Vinci robotic surgical system or laparoscopic surgical system

## Primary Outcomes

- **overall survival** _(time frame: 5 years after surgery)_ — months
- **disease-free survival** _(time frame: 5 years after surgery)_ — months

## Secondary Outcomes

- **the rate of postoperative complications** _(time frame: 1 months after surgery)_
- **operative time** _(time frame: Intraoperative)_
- **estimation of blood loss** _(time frame: Intraoperative)_
- **number of retrieved lymph nodes** _(time frame: Intraoperative)_
- **days after postoperative hospital stay** _(time frame: 1 months after surgery)_
- **time to first exhaust** _(time frame: 1 weeks after surgery)_
- **time to liquid diet** _(time frame: 1 weeks after surgery)_
- **the rate of intracorporeal anastomosis** _(time frame: 1 months after surgery)_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06454253.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06454253*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*